Posted by Michael Wonder on 19 Feb 2019
Big opportunities in big data, but EMA and industry just getting started
18 February 2019 - 250m genomes sequenced, but data trapped in silos.
The potential of big data to transform drug development and regulation is now established in biopharma, but Europe’s regulators and industry agree there is a long way to go to make this vision a reality.
That’s because while there has been an explosion in volumes and types of data being generated, a lack of common standards and regulations means these aren’t yet being fully exploited to streamline drug approval or monitoring.
